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AdjuvantAbstract Medullomyoblastoma (MMB) is a rare primitive neuro-epithelial tumor and seen in
mainly pediatric age group1. There have been about 50 cases reported so far in the literature. In
this report, we describe the clinical features and treatment of 4 cases of MMB.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Medullomyoblastoma (MMB) is a rare primitive neuro-
epithelial tumor and seen mainly in the pediatric age group
[1]. There have been about 50 cases reported so far in the
literature. In this report, we describe the clinical features and
treatment of 4 cases of MMB.
Case series
Three out of the 4 cases were children and the other case was
an adult of 32 years. Headache and vomiting were thepresenting complaints in 3 patients while ataxia was a present-
ing symptom in the fourth case. The median duration of symp-
toms before diagnosis was made was 5 months. All the 4 cases
presented with posterior fossa mass in contrast enhanced MRI
of the brain (see Fig. 1). The mass appeared contrast
enhancing on MRI and three of the 4 patients had obstructive
hydrocephalus. The preoperative radiological diagnosis was
Medulloblastoma (MB) in all the 4 cases. The clinical charac-
teristics are summarized in Table 1.
A gross total excision was achieved in 3 patients while in the
fourth a tumor decompression was achieved. Ventriculo-
peritoneal shunt was inserted in 3 cases before surgery.
Post-operative MRI revealed residual disease in 2 cases.
Histopathological examination revealed MMB. The MIB
labeling index was 45%, 60% and 80% in the 3 cases while
MIB labeling index was not available in the fourth case.
Immuno histo-chemistry was required for diagnosis
which revealed Glial ﬁbrillary acidic protein (GFAP) negativ-
ity while positive for synaptophysin, chromogranin and
Figure 1 Contrast enhanced MRI of a case of Medullomyoblastoma showing posterior fossa mass with contrast enhancement.
Table 1 Clinical characteristics of patients with medullomyoblastoma.
No Age
(years)
Gender Location Surgery VP
shunt
Stage Treatment Location Status at last follow up
1 4 Male Floor of fourth
ventricle
Decompression  M CSI + CT Floor of
fourth
ventricle
NED at 4 years
2 32 Male Cerebello-
pontine angle
GTR + M+ CSI + CT Cerebello-
pontine angle
Spinal metastasis after 5 months
and succumbed to disease
3 2 Male Cerebellum GTR + M+ CSI + CT Cerebellum NED at 6 months
4 3 Male Cerebellum GTR  M CSI + CT Cerebellum On adjuvant treatment
(NED – No evidence of disease; GTR – gross tumor resection; CSI – craniospinal irradiation; CT – chemotherapy, M+ – metastatic to spine).
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ﬂuid (CSF) positivity without drop metastasis in spinal MRI
while the second one revealed spinal drop metastasis. Other
2 cases were found negative in CSF and spinal MRI for
metastasis.
Adjuvant chemotherapy and cranio-spinal radiation were
given to all patients. Radiotherapy was given upfront in 2 cases
while radiotherapy was planned after chemo therapy in the
other 2 cases in view of age less than 3 years. The cranio-spinal
dose of 30 Gy was given to M disease while 36 Gy dose was
given in M+ cases followed by posterior fossa boost to a total
of 56 Gy. Patients received 6 cycles of adjuvant chemotherapy
with carboplatin dose of AUC-5 D1 and Etoposide 100 mg/m2
D1–3 repeated every 3 weeks. At the last follow up, three pedi-
atric patients had no evidence of disease while the adult patient
had spinal drop metastasis 5 months after treatment comple-
tion and succumbed to disease.Discussion
MMB was described ﬁrst by Marinesco and Goldstein in 1933
and is a rare histological variant of medulloblastoma [2]. It
consists of primitive neuroectodermal cells intermixed with
cells featuring myogenic differentiation [3]. MMB generally
occurs in the posterior fossa and mostly occurs in the pediatric
age group with a median age of 5 years (<10 age year). Male
predominance may be noted in these cases with an incidence of
up to 5% of all cases of medulloblastoma [4]. General charac-
teristics of PNETs including medulloblastoma include dissem-
ination through the cerebro spinal ﬂuid; poor differentiation
and high mitotic activity are also seen in medullomyoblas-
toma. These tumors are classiﬁed as WHO grade IV with
neuro-ectodermal and myoblastic components. The origin of
such tumors has been hypothesized as rhabdomyoblastic dif-
ferentiation of neuroectodermal cells derived from interphase
Medullomyoblastoma treated with craniospinal 111FISH experiment showing similar genetic changes in the neu-
roectodermal and the myoblastic components [5].
Due to the location of these tumors in the infra temporal
location these patients generally present with features of raised
intra cranial tension and cerebellar symptoms like medul-
loblastoma. In 1 case series of 6 patients reported by,
Mahapatra et al. the clinical presentation of those patients
was similar to the clinical presentation of patients in our report
[6].
The brain imaging of these patients may vary among
patients with heterogeneous enhancing and sometimes cystic
areas within and may mimic other PNETs. The detection of
biphasic nodularity in a cerebellar lesion may prove useful in
differentiating MMB from other tumors that arise in this loca-
tion [5]. In our report also the patients presented with enhanc-
ing mass in the infra temporal fossa and the radiological
diagnosis in all the 3 cases was medulloblastoma.
Microscopic examination of these tumors may show tumor
cells composed of sheets of small cells with oval to elongated
dark staining nuclei and scanty eosinophilic cytoplasm
exhibiting increased mitotic activity [1]. It may show discrete
rhabdomyoblastic and primitive neuroectodermal islands.
The cells resembling myoblasts may be positive for actin and
desmin. Immunohistochemical staining for synaptophysin
and neuron-speciﬁc Enolase revealed variable positivity in
these primitive neuroectodermal cells [5,7]. Helton et al., in a
review of 6 patients reported alterations in chromosome 17
or c-myc ampliﬁcation in 4 cases [5]. Polysomies of chromo-
somes 2, 8, 17 and 22q may be also found in MMB.
The management of MMB follows the protocol similar to
that of medulloblastoma due to rarity of this tumor. Tri-
modality therapies by a combination of surgery, radiotherapy
and chemotherapy have been generally used in the manage-
ment of MMB. Craniospinal irradiation remains an important
part in the adjuvant therapy of these tumors. Craniospinal
dose may be important like in case of medulloblastoma. In
the series by Mahapatra et al. in which a spinal RT dose of
only 15.0 Gy, the 6 patients who arrived postoperatively in
the study all died of disease within 3 years of diagnosis [6].
Various studies have used craniospinal dose ranging from
24.6 to 36 Gy [5]. In our report we used a craniospinal dose
of 30–36 Gy with a posterior boost of up to 56 Gy.
The adjuvant chemotherapy also varied widely between
various groups including regimens of lomustine, vincristine,
and cisplatin or carboplatin, cyclophosphamide, and vin-
cristine [5,8]. In our series, all patients received 6 cycles of adju-
vant chemotherapy with carboplatin and etoposide.
Most of the cases reported in the literature show a poor
outcome despite this aggressive approach in MMB unlike
medulloblastoma. Three out of 6 cases, reported by Helton
et al., died of the disease within 2 years [5]. So generally
MMBs behave especially aggressive in comparison to conven-
tional MBs [9]. But at the same time there has been case
reports reporting survival from 11 to 15 years [10]. In our
study 3 patients remained disease free at median follow up
of 5.5 months (3–48 months) after treatment completion whilethe second one had a recurrence within 5 months of
completion of treatment.
Conclusion
MMB clinically and radiologically behave similar to medul-
loblastoma. Immunohistochemistry may be important for dif-
ferentiating it from MB. The treatment approach is similar to
MB but even with a tri-modality approach the prognosis of
these patients remains dismal.
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